What Is GPC3?
Glypican-3 (GPC3) is a protein found on the surface of cells. In healthy adults, GPC3 is barely expressed in most tissues. However, in hepatocellular carcinoma (HCC), the most common type of primary liver cancer, GPC3 is often produced in large amounts on the surface of cancer cells. Studies have shown that GPC3 is overexpressed in roughly 70 to 80 percent of HCC tumors.
This makes GPC3 a useful biomarker. In pathology, GPC3 staining on biopsy samples has long been used to confirm whether a liver lesion is HCC. The idea behind GPC3 PET CT is to take this same principle and apply it to whole-body imaging, detecting GPC3-expressing tumors without the need for a biopsy.
The Challenge of Liver Lesion Characterization
The liver is a common site for both benign (non-cancerous) and malignant (cancerous) lesions. Hemangiomas, focal nodular hyperplasia, and regenerative nodules are all benign conditions that can appear in the liver. On the other hand, the liver can harbor primary cancers like HCC or receive metastatic deposits from cancers elsewhere in the body.
Conventional imaging with ultrasound, CT, and MRI can often distinguish between these lesions based on their appearance and how they behave with contrast agents. However, there are cases where the imaging findings are ambiguous, particularly in patients with cirrhosis (chronic liver scarring). In cirrhotic livers, the altered architecture makes it harder to confidently characterize small nodules. A nodule might be a regenerative change, a pre-cancerous dysplastic nodule, or early HCC.
FDG PET CT, the most widely used PET scan, has limited usefulness for HCC because well-differentiated (slower-growing) HCC tumors often do not take up FDG strongly. This gap in imaging is part of what makes a GPC3-targeted tracer valuable.
How GPC3 PET CT Works
A GPC3 PET CT scan uses a radioactive tracer that is designed to bind specifically to GPC3 protein on cell surfaces. The tracer is injected into a vein, circulates through the body, and attaches to cells that express GPC3. A PET CT scanner then detects the radioactive signal and produces detailed images showing exactly where GPC3-expressing cells are located.
Because GPC3 is highly specific to HCC (it is not typically found on normal liver cells or most other cancers), a positive signal on GPC3 PET CT strongly suggests the presence of hepatocellular carcinoma. This molecular specificity is what sets it apart from conventional anatomical imaging.
The scan itself follows the standard PET CT workflow. After the tracer injection, there is a waiting period to allow it to distribute and bind to its target. You then lie on the PET CT scanner table while images are acquired. The process is painless and non-invasive.
When GPC3 PET CT May Be Useful
Characterizing Indeterminate Liver Lesions
When a liver lesion is found on ultrasound, CT, or MRI but its nature remains unclear, GPC3 PET CT can add a layer of molecular information. If the lesion shows GPC3 uptake, it suggests HCC. If it does not, other diagnoses become more likely. This can sometimes reduce the need for invasive liver biopsy.
Staging HCC
In patients already diagnosed with HCC, GPC3 PET CT can help determine the full extent of disease. It may detect additional lesions within the liver or identify metastatic spread to other organs that were not visible on conventional imaging. Accurate staging is important for selecting the right treatment approach.
Monitoring Treatment Response
After treatments like transarterial chemoembolization (TACE), radiofrequency ablation, or systemic therapy, it can be difficult to tell whether residual tissue seen on CT or MRI is active cancer or scar tissue. A GPC3-targeted scan can help clarify this by showing whether the residual tissue still expresses the cancer biomarker.
Guiding Theranostic Approaches
One of the exciting aspects of GPC3 as a target is its potential for theranostics, where the same molecular target used for diagnosis can also be used for treatment. If GPC3 PET CT confirms that a tumor expresses GPC3, it opens the door to GPC3-targeted therapies, including radioligand therapy, antibody-drug conjugates, and other investigational approaches.
Current Status and Research
GPC3 PET CT is an area of active research. Several groups worldwide are developing and refining GPC3-targeting tracers, including antibody-based and peptide-based agents labelled with different radioactive isotopes. Early clinical studies have shown promising results, with GPC3 PET CT demonstrating the ability to detect HCC lesions that other imaging modalities missed.
However, this technology is still evolving. Availability is limited to specialized centers involved in research or early clinical adoption. The tracers, imaging protocols, and interpretation criteria are still being standardized. As more clinical data accumulates, GPC3 PET CT is expected to become more widely available.
What This Means for Patients
If you have been diagnosed with a liver condition or if a liver lesion has been found on routine imaging, your hepatologist or oncologist will guide you on the appropriate investigations. GPC3 PET CT is one of several tools available, and its use depends on your specific clinical situation. Not every liver lesion needs this scan, and your doctor will consider the full picture, including your medical history, blood tests (like alpha-fetoprotein levels), and findings from other imaging studies.
Advances in molecular imaging like GPC3 PET CT represent a step toward more precise and personalized liver cancer care. Speak with your treating physician or a nuclear medicine specialist to understand whether this imaging option is relevant to your situation.